Articles tagged "Cytomeglovirus"

2018 American Transplant Congress
Evaluation of Risk Factors for Progression of Low Level CMV Viremia in Solid Organ Transplant Recipients
Y. Natori, A. Humar, A. Alghamdi, D. Kumar.
Multi Organ Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada.
Background: Low level CMV viremia is common, and may either progress to higher viral loads that require therapy, or may spontaneously resolve. The clinical predictors…
2018 American Transplant Congress
T-Cell Depletion Does Not Increase the Risk of CMV Infection in Donor-Positive, Recipient-Negative Kidney Transplants Due to the Absence of Preformed CMV-Specific Cell-Mediated Immunity
M. Jarque,¹ H. Kaminski,² L. Couzi,² E. Crespo,¹ J. Déchanet-Merville,³ S. Luque,¹ N. Montero,⁴ M. Pascual,⁵ O. Manuel,^5,6 P. Merville,² O. Bestard.^1,4
¹Nephrology Lab, IDIBELL, Barcelona, Spain; ²Nephrology Dep, Hôpital Pellegrin, Bordeaux, France; ³National Center of Scientific Research, Bordeaux, France; ⁴Nephrology Dep, Bellvitge Hospital, Barcelona, Spain; ⁵Transplantation Center, Lausanne Hospital, Lausanne, Switzerland; ⁶Infectious Diseases Dep, Lausanne Hospital, Lausanne, Switzerland.
Kidney transplants (KT) with R-/D+ CMV serostatus receiving T-cell depletion induction are considered as the highest risk population for CMV infection and long-lasting prophylaxis therapy…
2018 American Transplant Congress
Acute Murine CMV Infection Results in Loss of Intragraft CD73^HIFR4^HIPD1⁺ CD4 T Cells and Graft Rejection in Previously Tolerant Recipients
A. Dangi,¹ L. Zhang,¹ X. Zhang,² X. Luo.^1,2
¹Division of Nephrology and Hypertension, Department of Medicine, Northwestern University, Chicago, IL; ²Comprehensive Transplant Center, Department of Surgery, Northwestern University, Chicago, IL.
Background: Transplantation tolerance in human recipients has been achieved in recent trials. Nevertheless, the impact of highly prevalent and clinically relevant cytomegalovirus (CMV) infection on…
2018 American Transplant Congress
Humoral Immunity to CMV Remains Intact after Dual Targeting Desensitization in Allosensitized Nonhuman Primates
P. Schroder, B. Ezekian, F. Saccoccio, J. Yoon, M. Dennis, K. Freischlag, J. Kwun, S. Permar, S. Knechtle.
Department of Surgery, Duke University Medical Center, Durham, NC.
Desensitization to remove donor specific antibody (DSA) is a way to expand the pool of potential donors for sensitized patients. This study compared the effects…
2018 American Transplant Congress
CMV Mismatch Still Negatively Affects Patient and Graft Survival in the Era of CMV Prophylactic and Preemptive Therapy: A Paired Kidney Analysis
N. Leeaphorn,¹ N. Garg,² N. Thamcharoen,¹ E. Khankin,¹ F. Cardarelli,¹ M. Pavlakis.¹
¹Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA; ²Department of Medicine, Nephrology Division, University of Wisconsin School of Medicine, Madison, WI.
Background: The impact of CMV serostatus on kidney transplant outcomes in an era when CMV prophylactic and preemptive strategies are used routinely is not clearly…
2018 American Transplant Congress
The Influence of Rabbit Antithymocyte Globulin (rATG) Dose on the Incidence of CMV Infection in Kidney Transplant Recipients Receiving No Pharmacological Prophylaxis. A Propensity Score Matched Cohort Analysis
M. Ivani de Paula,^1,2 S. Bae,¹ J. Garonzik-Wang,¹ C. Felipe,² M. Cristelli,² A. Massie,^1,3 J. Medina-Pestana,² D. Segev,^1,3 H. Tedesco Silva J�nior.²
¹Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD; ²Department of Nephrology, Hospital do Rim, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; ³Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD, Brazil.
rATG has become the agent of choice for induction therapy in sensitized patients and those receiving expanded criteria donors (ECD) allografts. However, the optimal dose…
2018 American Transplant Congress
Outcomes of Hispanic Kidney Transplant Recipients under a Cyclosporine versus Tacrolimus Based Immunosuppression Protocol
P. West-Thielke, M. Campara, I. Tang, E. Benedetti.
University of Illinois, Chicago.
Purpose: In 2005, an internal retrospective review of kidney transplant recipients (KTx) showed a higher incidence of post transplant diabetes mellitus (PTDM) for Hispanic patients…
2018 American Transplant Congress
An Individualized Strategy Using Virus and Immune-Based Markers to Prevent Cytomegalovirus Disease after Face Transplantation
R. Razonable, H. Amer, S. Mardini.
Mayo Clinic, Rochester, MN.
Introduction: There is limited data on CMV prevention after face transplantation. We report an individualized approach using prophylaxis followed by surveillance and preemptive therapy guided…
2018 American Transplant Congress
Assessment of Anti-CMV Immunity by Monitoring Anti-CMV Antibody (CMV-Ab) and CMV-Specific Cytotoxic T Cells (CMV-Tc) in Pediatric Kidney Transplant Recipients (Ped KTx Pts)
B. Shin,¹ H. Pizzo,² S. Jordan,² D. Lovato,¹ A. Petrosyan,¹ D. Puliyanda,² M. Toyoda.¹
¹Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA; ²Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: CMV infection results in significant morbidity in KTx pts, especially CMV sero- ped pts with CMV sero+ donors (D+/R-). CMV infection is controlled primarily…
2018 American Transplant Congress
CMV Viremia and Development of CMV-Specific Cytotoxic T-Cells (CMV-Tc) in Pediatric Renal Transplant Recipients
H. Pizzo, B. Shin, M. Toyoda, S. Jordan, D. Puliyanda.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Background: The use of lymphocyte depleting agents (LDA) for induction immunosuppression among renal transplant (tx) recipients raises concern for the increased susceptibility to viral infections,…